1. Home
  2. HALO vs CORT Comparison

HALO vs CORT Comparison

Compare HALO & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$107.94

Market Cap

11.2B

Sector

Health Care

ML Signal

HOLD

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

HOLD

Current Price

$120.92

Market Cap

9.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HALO
CORT
Founded
1998
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2B
9.7B
IPO Year
2001
2001

Fundamental Metrics

Financial Performance
Metric
HALO
CORT
Price
$107.94
$120.92
Analyst Decision
Buy
Buy
Analyst Count
11
5
Target Price
$78.64
$96.50
AVG Volume (30 Days)
2.3M
1.1M
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
3.11
0.09
Revenue
$151,862,000.00
$761,407,000.00
Revenue This Year
$28.24
$26.08
Revenue Next Year
$12.56
$26.98
P/E Ratio
$34.12
$1,345.00
Revenue Growth
N/A
12.79
52 Week Low
$61.23
$28.66
52 Week High
$107.96
$122.21

Technical Indicators

Market Signals
Indicator
HALO
CORT
Relative Strength Index (RSI) 78.97 70.05
Support Level $67.12 $77.73
Resistance Level N/A $122.21
Average True Range (ATR) 3.59 3.53
MACD 0.96 0.20
Stochastic Oscillator 98.87 84.57

Price Performance

Historical Comparison
HALO
CORT

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: